Manufacturer
PFIZER (PERTH) PTY. LTD.
Contents
Idarubicin HCl
Indication
Acute non-lymphocytic leukemia (ANLL) in adult for remission induction in untreated, relapsed or refractory patients; acute lymphocytic leukemia (ALL) as 2nd-line treatment in adult & childn.
Instruction
Adult ANLL 12 mg/m2 IV daily for 3 days in combination w/ cytarabine or 8 mg/m2 IV daily for 5 days as single agent or in combination. ALL Adult 12 mg/m2 single dose IV daily for 3 days. Childn 10 mg/m2 single dose IV daily for 3 days.
Drug interaction
Other potentially cardiotoxic drugs & cardioactive compd. Additive myelosuppressant effect w/ radiotherapy.
Malaysia
